Literature DB >> 17372216

An acquired hypocalciuric hypercalcemia autoantibody induces allosteric transition among active human Ca-sensing receptor conformations.

Noriko Makita1, Junichiro Sato, Katsunori Manaka, Yuki Shoji, Atsuro Oishi, Makiko Hashimoto, Toshiro Fujita, Taroh Iiri.   

Abstract

The seven-spanning calcium-sensing receptor (CaSR) activates multiple G proteins including Gq and Gi, and thereby activates a variety of second messengers and inhibits parathyroid hormone (PTH) secretion. However, the exact signaling mechanisms underlying the functional activity of CaSR are not yet fully understood. The heterozygous inactivation of CaSR or its inhibition by antibody blocking results in either familial hypocalciuric hypercalcemia or acquired hypocalciuric hypercalcemia (AHH), respectively. Here, we report the identification of a unique CaSR autoantibody in an AHH patient. Paradoxically, we find that this autoantibody potentiates the Ca(2+)/Gq-dependent accumulation of inositol phosphates by slightly shifting the dose dependence curve of the Ca(2+) mediated activation of phosphatidylinositol turnover to the left, whereas it inhibits the Ca(2+)/Gi-dependent phosphorylation of ERK1/2 in HEK293 cells stably expressing human CaSR. Treatment of these same cells with a calcimimetic, NPS-R-568, augments the CaSR response to Ca(2+), increasing phosphatidylinositol turnover and ERK1/2 phosphorylation, and overcoming the autoantibody effects. Our observations thus indicate that a calcium-stimulated CaSR primed by a specific autoantibody adopts a unique conformation that activates Gq but not Gi. Our findings also suggest that CaSR signaling may act via both Gq and Gi to inhibit PTH secretion. This is the first report of a disease-related autoantibody that functions as an allosteric modulator and maintains G protein-coupled receptors (GPCRs) in a unique active conformation with its agonist. We thus speculate that physiological modulators may exist that enable an agonist to specifically activate only one signaling pathway via a GPCR that activates multiple signaling pathways.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17372216      PMCID: PMC1838439          DOI: 10.1073/pnas.0701290104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

Review 1.  Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors.

Authors:  Roland Seifert; Katharina Wenzel-Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2002-09-06       Impact factor: 3.000

Review 2.  Constitutive activity and inverse agonists of G protein-coupled receptors: a current perspective.

Authors:  Graeme Milligan
Journal:  Mol Pharmacol       Date:  2003-12       Impact factor: 4.436

Review 3.  Seven-transmembrane receptors.

Authors:  Kristen L Pierce; Richard T Premont; Robert J Lefkowitz
Journal:  Nat Rev Mol Cell Biol       Date:  2002-09       Impact factor: 94.444

Review 4.  Signal transduction in the parathyroid.

Authors:  Olga Kifor; Imre Kifor; Edward M Brown
Journal:  Curr Opin Nephrol Hypertens       Date:  2002-07       Impact factor: 2.894

Review 5.  Angiotensin AT1/AT2 receptors: regulation, signalling and function.

Authors:  Elena Kaschina; Thomas Unger
Journal:  Blood Press       Date:  2003       Impact factor: 2.835

6.  Stimulation of extracellular signal-regulated kinases and proliferation in rat osteoblastic cells by parathyroid hormone is protein kinase C-dependent.

Authors:  J T Swarthout; T A Doggett; J L Lemker; N C Partridge
Journal:  J Biol Chem       Date:  2000-12-06       Impact factor: 5.157

7.  Mitogen-activated protein kinase cascade in human normal and tumoral parathyroid cells.

Authors:  S Corbetta; A Lania; M Filopanti; L Vicentini; E Ballaré; A Spada
Journal:  J Clin Endocrinol Metab       Date:  2002-05       Impact factor: 5.958

8.  Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors.

Authors:  Mounia Azzi; Pascale G Charest; Stéphane Angers; Guy Rousseau; Trudy Kohout; Michel Bouvier; Graciela Piñeyro
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-17       Impact factor: 11.205

9.  A syndrome of hypocalciuric hypercalcemia caused by autoantibodies directed at the calcium-sensing receptor.

Authors:  Olga Kifor; Francis D Moore; Miriam Delaney; Jeffrey Garber; Geoffrey N Hendy; Robert Butters; Ping Gao; Thomas L Cantor; Imre Kifor; Edward M Brown; John Wysolmerski
Journal:  J Clin Endocrinol Metab       Date:  2003-01       Impact factor: 5.958

10.  Calcium-sensing receptor-mediated ERK1/2 activation requires Galphai2 coupling and dynamin-independent receptor internalization.

Authors:  Deborah M Holstein; Kelly A Berg; L M Fredrik Leeb-Lundberg; Merle S Olson; Christine Saunders
Journal:  J Biol Chem       Date:  2003-12-30       Impact factor: 5.157

View more
  28 in total

1.  V2 vasopressin receptor (V2R) mutations in partial nephrogenic diabetes insipidus highlight protean agonism of V2R antagonists.

Authors:  Kazuhiro Takahashi; Noriko Makita; Katsunori Manaka; Masataka Hisano; Yuko Akioka; Kenichiro Miura; Noriyuki Takubo; Atsuko Iida; Norishi Ueda; Makiko Hashimoto; Toshiro Fujita; Takashi Igarashi; Takashi Sekine; Taroh Iiri
Journal:  J Biol Chem       Date:  2011-12-05       Impact factor: 5.157

2.  Human Neuropeptide S Receptor Is Activated via a Gαq Protein-biased Signaling Cascade by a Human Neuropeptide S Analog Lacking the C-terminal 10 Residues.

Authors:  Yuan Liao; Bin Lu; Qiang Ma; Gang Wu; Xiangru Lai; Jiashu Zang; Ying Shi; Dongxiang Liu; Feng Han; Naiming Zhou
Journal:  J Biol Chem       Date:  2016-02-10       Impact factor: 5.157

Review 3.  Emerging paradigms in GPCR allostery: implications for drug discovery.

Authors:  Denise Wootten; Arthur Christopoulos; Patrick M Sexton
Journal:  Nat Rev Drug Discov       Date:  2013-08       Impact factor: 84.694

4.  Regulation of RhoA signaling by the cAMP-dependent phosphorylation of RhoGDIα.

Authors:  Atsuro Oishi; Noriko Makita; Junichiro Sato; Taroh Iiri
Journal:  J Biol Chem       Date:  2012-09-25       Impact factor: 5.157

Review 5.  Autoantibodies as Endogenous Modulators of GPCR Signaling.

Authors:  Meredith A Skiba; Andrew C Kruse
Journal:  Trends Pharmacol Sci       Date:  2020-12-24       Impact factor: 14.819

6.  Seven transmembrane G protein-coupled receptor repertoire of gastric ghrelin cells.

Authors:  Maja S Engelstoft; Won-Mee Park; Ichiro Sakata; Line V Kristensen; Anna Sofie Husted; Sherri Osborne-Lawrence; Paul K Piper; Angela K Walker; Maria H Pedersen; Mark K Nøhr; Jie Pan; Christopher J Sinz; Paul E Carrington; Taro E Akiyama; Robert M Jones; Cong Tang; Kashan Ahmed; Stefan Offermanns; Kristoffer L Egerod; Jeffrey M Zigman; Thue W Schwartz
Journal:  Mol Metab       Date:  2013-09-04       Impact factor: 7.422

7.  Activating autoantibodies against the calcium-sensing receptor detected in two patients with autoimmune polyendocrine syndrome type 1.

Authors:  E Helen Kemp; Nikos G Gavalas; Kai J E Krohn; Edward M Brown; Philip F Watson; Anthony P Weetman
Journal:  J Clin Endocrinol Metab       Date:  2009-10-16       Impact factor: 5.958

Review 8.  Minireview: the intimate link between calcium sensing receptor trafficking and signaling: implications for disorders of calcium homeostasis.

Authors:  Gerda E Breitwieser
Journal:  Mol Endocrinol       Date:  2012-06-28

9.  Analysis of the V2 Vasopressin Receptor (V2R) Mutations Causing Partial Nephrogenic Diabetes Insipidus Highlights a Sustainable Signaling by a Non-peptide V2R Agonist.

Authors:  Noriko Makita; Tomohiko Sato; Yuki Yajima-Shoji; Junichiro Sato; Katsunori Manaka; Makiko Eda-Hashimoto; Masanori Ootaki; Naoki Matsumoto; Masaomi Nangaku; Taroh Iiri
Journal:  J Biol Chem       Date:  2016-09-06       Impact factor: 5.157

Review 10.  Physiology and pathophysiology of the calcium-sensing receptor in the kidney.

Authors:  Daniela Riccardi; Edward M Brown
Journal:  Am J Physiol Renal Physiol       Date:  2009-11-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.